미국의 항독소 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 유형별, 작용기전별, 최종 용도별, 부문별 예측(2025-2030년)

U.S. Anti-Venom Market Summary

The U.S. anti-venom market size was estimated at USD 424.5 million in 2024 and is projected to reach USD 670.0 million by 2030, growing at a CAGR of 8.0% from 2025 to 2030. The market is expanding due to the rising incidence of venomous bites and stings, especially from snakes and insects.

Increased human interaction with venomous species is fueled by urbanization, deforestation, and climate change, which have impacted the habitats of these animals and brought them closer to populated areas. This trend has heightened the need for effective anti-venom treatments to reduce fatalities and long-term health complications associated with envenomation, driving the U.S. anti-venom industry.

Advancements in biotechnology significantly contribute to market growth. Innovations such as monoclonal antibody-based anti-venoms and recombinant DNA technologies have resulted in the development of more potent, safer, and targeted therapies. These improvements enhance treatment outcomes and help reduce production costs, making anti-venoms more accessible. The continuous research and development efforts by pharmaceutical companies and research institutions, particularly in the U.S., foster innovation and the introduction of advanced anti-venom products tailored to specific venom types.

The U.S. market benefits from a robust healthcare system that facilitates rapid access to anti-venom treatments in emergency settings. The prevalence of outdoor recreational activities and expanding urban development into wildlife habitats increases the likelihood of encounters with venomous species, thereby driving market demand. Moreover, the presence of key industry players and ongoing government support for pharmaceutical innovation strengthen the market's growth prospects.

U.S. Anti-Venom Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. anti-venom market report based on species, type, mode of action, and end use.

• Species Outlook (Revenue, USD Million, 2018 - 2030)
• Snake
  • Common Cobra
  • Common Krait
  • Russell Viper
  • Others
• Scorpion
• Spider
• Other
• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Polyvalent
• Monovalent
• Mode of Action Outlook (Revenue, USD Million, 2018 - 2030)
• Cytotoxic
• Neurotoxic
• Hemotoxic
• Cardiotoxic
• Myotoxic
• Others
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Clinics
• Ambulatory Surgical Centers

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Species
  • 1.2.2. Type
  • 1.2.3. Mode of action
  • 1.2.4. End use
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Species outlook
  • 2.2.2. Type outlook
  • 2.2.3. Mode of action outlook
  • 2.2.4. End use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Anti-Venom Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Anti-Venom Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. U.S. Anti-Venom Market: Pipeline Analysis

Chapter 4. U.S. Anti-Venom Market: Species Estimates & Trend Analysis

• 4.1. Species Segment Dashboard
• 4.2. U.S. Anti-Venom Market: Species Movement Analysis
• 4.3. U.S. Anti-Venom Market Size & Trend Analysis, by Species, 2018 to 2030 (USD Million)
• 4.4. Snake
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Common Cobra
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Common Krait
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Russell Viper
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Scorpion
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Spider
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Other
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Anti-Venom Market: Type Estimates & Trend Analysis

• 5.1. Type Segment Dashboard
• 5.2. U.S. Anti-Venom Market: Type Movement Analysis
• 5.3. U.S. Anti-Venom Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 5.4. Polyvalent
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Monovalent
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Anti-Venom Market: Mode of Action Estimates & Trend Analysis

• 6.1. Mode of Action Segment Dashboard
• 6.2. U.S. Anti-Venom Market: Mode of Action Movement Analysis
• 6.3. U.S. Anti-Venom Market Size & Trend Analysis, by Mode of Action, 2018 to 2030 (USD Million)
• 6.4. Cytotoxic
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Neurotoxic
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Hemotoxic
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Cardiotoxic
  • 6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Myotoxic
  • 6.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Others
  • 6.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Anti-Venom Market: End Use Estimates & Trend Analysis

• 7.1. End Use Segment Dashboard
• 7.2. U.S. Anti-Venom Market: End Use Movement Analysis
• 7.3. U.S. Anti-Venom Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Hospitals
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Clinics
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Ambulatory Surgical Centers
  • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company heat map analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Boehringer Ingelheim
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. CSL Limited
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Merck & Co., Inc.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Pfizer, Inc.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives